GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
Status:
Terminated
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This is a 24-week randomized, double-blind, multi-center, placebo-controlled study of
tesaglitazar in patients with type 2 diabetes who are not adequately controlled on insulin
(along or in combination with one or more oral antidiabetic agents in addition to diet and
lifestyle advice). The study comprises a 3-week enrollment period and a 24-week randomized,
double blind, multi-center, placebo-controlled treatment period and a 3-week follow-up.
Patients must receive at least 30 units of insulin per day and will continue their current
oral antidiabetic treatment regimen throughout the study.